Diabetes Summit (DBT2011)
|Event Date/Time: Mar 07, 2011||End Date/Time: Mar 08, 2011|
The International Diabetes Federation estimates that more than 285 million people world-wide have diabetes and 438 million people will have this disease within 20 years. Type 2 Diabetes Mellitus (T2DM) accounts for more than 90% of all diabetes and is characterized by insulin resistance combined with relatively reduced insulin secretion. The seven major markets for diabetes are expected to grow to 35 billion in 10 years driven by patient population expansion and novel therapies. With more than 400 drug candidates for diabetes in active development and in light of the recent US Food and Drug Administration (FDA) guidance to assess cardiovascular risk in clinical trials, the burden to develop novel drugs is greater and the barrier for success has become higher than ever. What will be the next block-buster drug target for T1DM and T2DM? How does the recent FDA guidance affect our approach to develop new medications for diabetes? How do different size companies adapt the best strategy to be competitive in this field?
Come and join other diabetes experts at GTCbioâ€™s Diabetes Summit and hear key thought-leader`s opinions to these questions and many more. This important meeting will be held on March 7-8, 2011 in Philadelphia, PA. The conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current clinical drug development, and business strategies and opportunities under the current regulatory landscape.
This summit includes two concurrent tracks:
Diabetes Drug Discovery and Development
Diabetes Drugs Partnering & Deal-making
2011 Conference Advisory Committee